Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 38
- Registration Number
- NCT00059930
- Locations
- 🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Advanced Cancer of the Oropharynx or Hypopharynx
- Conditions
- First Posted Date
- 2003-04-30
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 160
- Registration Number
- NCT00003627
- Locations
- 🇫🇷
Centre Antoine Lacassagne, Nice, France
🇫🇷Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, Montpellier, France
🇫🇷Institut Jean Godinot, Reims, France
Oxaliplatin and Fluorouracil Plus Radiation Therapy in Treating Patients With Primary Esophageal or Stomach Cancer
- Conditions
- First Posted Date
- 2003-04-18
- Last Posted Date
- 2013-03-26
- Lead Sponsor
- Albany Medical College
- Registration Number
- NCT00004257
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Royal Liverpool University Hospital
- Target Recruit Count
- 1030
- Registration Number
- NCT00058201
- Locations
- 🇦🇺
Institute of Oncology at Prince of Wales Hospital, Randwick, New South Wales, Australia
🇦🇺Flinders Medical Centre, Bedford Park, South Australia, Australia
🇮🇹Policlinico Borgo Roma, Verona, Italy
Radiation Therapy With or Without Chemotherapy in Reducing Mouth Dryness in Patients With Nasopharyngeal Cancer
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 68
- Registration Number
- NCT00057785
- Locations
- 🇺🇸
Siteman Cancer Center at Barnes-Jewish Hospital, St Louis, Missouri, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸Radiological Associates of Sacramento Medical Group, Incorporated, Sacramento, California, United States
Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2016-03-23
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 1608
- Registration Number
- NCT00058474
Radiation Therapy and Paclitaxel, Carboplatin, and Fluorouracil Followed by Esophagectomy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
- Conditions
- Interventions
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 56
- Registration Number
- NCT00022139
- Locations
- 🇺🇸
Cancer Center of Kansas, PA - El Dorado, El Dorado, Kansas, United States
🇺🇸Southwest Medical Center, Liberal, Kansas, United States
🇺🇸Cancer Center of Kansas, PA - Newton, Newton, Kansas, United States
Combination Chemotherapy in Treating Women With Stage I Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2013-06-18
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 1512
- Registration Number
- NCT00055679
- Locations
- 🇫🇷
Institut Sainte Catherine, Avignon, France
🇫🇷Polyclinique Bordeaux Nord Aquitaine, Boucher, France
🇫🇷Centre Hospitalier Docteur Duchenne, Boulogne Sur Mer, France
Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer
- Conditions
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2012-07-04
- Target Recruit Count
- 16
- Registration Number
- NCT00055822
- Locations
- 🇺🇸
San Antonio Cancer Institute, San Antonio, Texas, United States
Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2018-06-15
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 97
- Registration Number
- NCT00055601
- Locations
- 🇺🇸
Utah Cancer Specialists at UCS Cancer Center, Salt Lake City, Utah, United States
🇺🇸LDS Hospital, Salt Lake City, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.